Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response
Authors:
- 1 March 2008
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 67 (3) , 340-345
Abstract
Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS). This is the first report on the treatment with infliximab over 5 years. Methods: As part of a multicentre randomised trial, 69 patients with active AS at baseline (BL) have been continuously treated with infliximab (5 mg/kg i.v. every 6 weeks)—except for a short discontinuation after 3 years (FU1). The primary outcome of this extension was remission according to the ASsessment in Ankylosing Spondylitis (ASAS) criteria at the end of year 5 of the study (FU2). Results: Of the 43 patients who completed year 3, 42 agreed to continue, 38 of which (90.5%) finished year 5 (55% of 69 initially). Partial clinical remission was achieved in 13 of 38 patients (34.2%) at FU1 and FU2. At FU2, the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 2.5±1.9 (BL:6.4, FU1:2.5). BASDAI values Conclusions: Infliximab is safe and efficacious in AS patients over 5 years. The majority of the patients remained on treatment and had rather persistent levels of low disease activity. Different response types could be identified.Keywords
This publication has 27 references indexed in Scilit:
- Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formationAnnals of the Rheumatic Diseases, 2007
- Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomesArthritis & Rheumatism, 2006
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?Annals of the Rheumatic Diseases, 2005
- Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2005
- What is the most appropriate radiologic scoring method for ankylosing spondylitis?Arthritis & Rheumatism, 2004
- The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R))Rheumatology, 2004
- Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2004
- Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three‐month, randomized, placebo‐controlled trialArthritis & Rheumatism, 2003
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992